These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 3258143)

  • 1. In vitro activities of five new quinolones against 88 genital and neonatal Haemophilus isolates.
    Quentin R; Koubaa N; Cattier B; Gavignet M; Goudeau A
    Antimicrob Agents Chemother; 1988 Jan; 32(1):147-9. PubMed ID: 3258143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [In vitro activity of new quinolones against Mycoplasma pathogenic to humans].
    Renaudin H; Quentin C; de Barbeyrac B; Bebear C
    Pathol Biol (Paris); 1988 May; 36(5):496-9. PubMed ID: 3136430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro activities of pefloxacin, ofloxacin, enoxacin and ciprofloxacin against 256 clinical isolates.
    Arpi M; Gahrn-Hansen B; Søgaard P; Bentzon MW
    Acta Pathol Microbiol Immunol Scand B; 1987 Apr; 95(2):141-6. PubMed ID: 3473910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibility of aerobic gram-negative blood culture isolates to oxolinic acid, norfloxacin, ciprofloxacin, enoxacin, pefloxacin, ofloxacin and oxo-enoxacin.
    Van der Auwera P
    Infection; 1986; 14(3):142-4. PubMed ID: 2942489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The comparative activity of twelve 4-quinolone antimicrobials against Haemophilus influenzae and Streptococcus pneumoniae.
    Ridgway GL; O'Hare MD; Felmingham D; Grüneberg RN
    Drugs Exp Clin Res; 1985; 11(4):259-62. PubMed ID: 2941258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vitro activity of newer quinolones against aerobic bacteria.
    Auckenthaler R; Michéa-Hamzehpour M; Pechère JC
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():29-39. PubMed ID: 2940214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The comparative in-vitro activity of eight newer quinolones and nalidixic acid.
    King A; Phillips I
    J Antimicrob Chemother; 1986 Nov; 18 Suppl D():1-20. PubMed ID: 3468100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative in vitro activity of seven quinolones against 100 clinical isolates of Clostridium difficile.
    Delmee M; Avesani V
    Antimicrob Agents Chemother; 1986 Feb; 29(2):374-5. PubMed ID: 2940968
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activities of ciprofloxacin, enoxacin, norfloxacin, ofloxacin and pefloxacin against Bacteroides fragilis and Clostridium difficile.
    Edlund C; Nord CE
    Scand J Infect Dis; 1986; 18(2):149-51. PubMed ID: 2939556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative in-vitro activity of five fluoroquinolones against mycobacteria.
    Davies S; Sparham PD; Spencer RC
    J Antimicrob Chemother; 1987 May; 19(5):605-9. PubMed ID: 3112094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative in vitro activity of amifloxacin and five other fluoroquinolone antimicrobial agents and preliminary criteria for the disk susceptibility test.
    Barry AL; Jones RN
    Eur J Clin Microbiol; 1987 Apr; 6(2):179-82. PubMed ID: 3474145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The comparative in-vitro activity of pefloxacin.
    King A; Phillips I
    J Antimicrob Chemother; 1986 Apr; 17 Suppl B():1-10. PubMed ID: 2940213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative antimicrobial activity of enoxacin, ciprofloxacin, amifloxacin, norfloxacin and ofloxacin against 177 bacterial isolates.
    Bassey CM; Baltch AL; Smith RP
    J Antimicrob Chemother; 1986 May; 17(5):623-8. PubMed ID: 2941401
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparative in vitro activity of 10 new 4-quinolones against enteropathogenic bacteria].
    Habiyaremye I; Verbist L; Vandepitte J
    Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):800-4. PubMed ID: 3116489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In-vitro activity of six fluorinated quinolones against Mycobacterium tuberculosis.
    Berlin OG; Young LS; Bruckner DA
    J Antimicrob Chemother; 1987 May; 19(5):611-5. PubMed ID: 3112095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [New oral quinolone compounds in chronic bronchitis].
    Davies BI; Maesen FP; Teengs JP; Baur C
    Infection; 1986; 14 Suppl 1():S73-8. PubMed ID: 2937739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The in-vitro activities of enoxacin and ofloxacin compared with that of ciprofloxacin.
    King A; Shannon K; Phillips I
    J Antimicrob Chemother; 1985 May; 15(5):551-8. PubMed ID: 3159712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect ofloxacin on Haemophilus influenza, Streptococcus pneumoniae and Neisseria meningitidis. Comparison with similar molecules].
    Dabernat H; Delmas C; Lareng MB
    Pathol Biol (Paris); 1985 May; 33(5):385-8. PubMed ID: 3162140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro evaluation of A-56619 and A-56620, two new quinolones.
    Barry AL; Thornsberry C; Jones RN
    Antimicrob Agents Chemother; 1986 Jan; 29(1):40-3. PubMed ID: 2942099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A review on the impact of 4-quinolones on the normal oropharyngeal and intestinal human microflora.
    Edlund C; Nord CE
    Infection; 1988; 16(1):8-12. PubMed ID: 3283041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.